Diabetic Peripheral Neuropathic Pain

Assets addressing this indication.

Total attributable cost

$56.9B

$9,349/patient

Drug spend

Not yet sourced

How this is calculated ↗

All severities · US

Company

Collegium Pharmaceutical, Inc. (BioDelivery Sciences International, acquired 2022) (1)Daiichi Sankyo (1)Eli Lilly (2)Grünenthal GmbH (2)Haisco Pharmaceutical Group (1)Hypera S.A. (Brainfarma Indústria Química e Farmacêutica S/A, wholly-owned subsidiary) (1)Jemincare (1)Jiangsu Hengrui Pharmaceuticals (1)JMackem Co., Ltd. (1)Johnson & Johnson (1)Lexicon Pharmaceuticals (1)NeurogesX, Inc. (dissolved/wound down) (1)Novaremed Ltd. (subsidiary of Novaremed AG) (1)Pfizer (1)Shanghai Huilun Pharmaceutical Co., Ltd. (1)Sun Pharmaceutical Industries (1)Vertex Pharmaceuticals (2)Viatris (1)WinSanTor (1)

16 of 16 assets

AJH-2947

Small moleculePhase 1

Capsaicin (Qutenza) · Qutenza

Small moleculeApproved

Crisugabalin

Small moleculePhase 3

Duloxetine · Cymbalta

Small moleculeApproved

HL-1186

Small moleculePhase 2

HRS-2129